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Abstract
Background: Generation of new reagents that can be used to screen or monitor HIV-1-specific responses constituted an
interesting field in the development of HIV vaccines to improve their efficacy.
Methods: We have evaluated the specific T cell response against different types of NL4-3 virions (including NL4-3 aldrithiol-2
treated, NL4-3/DRT and R5 envelopes: NL4-3/DRT/DEnv[AC10] and NL4-3/DRT/DEnv[Bal]) and against pools of overlapping
peptides (15 mer) encompassing the HIV-1 Gag and Nef regions. Cryopreserved PBMC from a subset of 69 chronic
asymptomatic HIV positive individuals have been employed using different techniques including IFN-c ELISPOT assay,
surface activation markers and intracellular cytokine staining (ICS) by flow cytometry.
Results: The differential response obtained against NL4-3 aldrithiol-2 treated and NL4-3/DRT virions (25% vs 55%,
respectively) allow us to divide the population in three groups: ‘‘full-responders’’ (positive response against both viral
particles), ‘‘partial-responders’’ (positive response only against NL4-3/DRT virions) and ‘‘non-responders’’ (negative responses).
There was no difference between X4 and R5 envelopes. The magnitude of the total responses was higher against NL4-3/DRT
and was positively correlated with gender and inverse correlated with viral load. On the contrary CD4+ T cell count was not
associated with this response. In any case responses to the viruses tended to be lower in magnitude than those detected by
the overlapping peptides tested. Finally we have found an increased frequency of HLA-B27 allele (23% vs 9%) and a
significant reduction in some activation markers (CD69 and CD38) on T cells surface in responders vs non-responders
individuals.
Conclusions: In summary these virions could be considered as alternative and useful reagents for screening HIV-1-specific T
cell responses in HIV exposed uninfected people, HIV infected patients and to assess immunogenicity of new prototypes
both in vitro and in vaccine trials, by a feasible, simply, effective and low cost assay.
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Introduction
During natural course of HIV-1 infection there is a gradual
increase in HIV-1 RNA viremia in parallel with impairment on
functional HIV-1-specific CD4+ and CD8+ T cell responses. At
the end of this process a state of severe immunodeficiency emerges
in HIV-1 infected individuals. Recent studies suggest that the
induction of HIV-1-specific CD4+ T helper cells and polyfunc-
tional CD8+ T cells could play an important role in controlling
HIV-1 replication and spread in patients with HIV-1 infection [1–
4]. Thus, a vaccine regimen capable of inducing broadly reactive
HIV-specific CD4+ and CD8+ T-cell responses may be required.
One of the major challenges in vaccine development is the
limited understanding of the correlates of immune protection [5].
So, an accurate and efficient monitoring and characterisation of
HIV-1-specific T-cells is very important to understand the
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e58927
pathogenesis of HIV-1 infection as well as to determine potential
efficacy of HIV-1 vaccines and immune-based therapies. Nowa-
days, technologies used to quantify and analyze HIV-specific T
cell responses are quite efficient but expensive and laborious [6–7].
In fact, and due to the high variability of the HIV, most of these
techniques do not allow detecting immune T cell responses against
different variable sequences of the autologous virus. So, there is an
important need to develop new reagents able to be more closely
related to the HIV native virus and to simulate or use a
mechanism of infection more similar to the physiological one.
In this sense and attending to this differential and important role
for RT, our group has recently reported the construction and
characterization of retrotranscriptase defective virions (NL4-3/
DRT) [8] to improve safety as a future candidate for being used in
HIV therapeutic vaccines. These attenuated constructs prevent
viral integration and further replication thus avoiding evolution
towards a pathogenic variant with a total deletion of the gene
coding RT. On the other side, these defective virions preserved the
structural integrity and are able to interact with antigen presenting
cells, thus allowing protein processing and T cell presentation. The
primary objective of the present work was to further analyse the
in vitro immunogenicity of these virions throwing light on some
aspects such as the importance of different tropism (X4 and R5
variants) or the magnitude of their response in comparison to the
elicited by a pool of peptides encompassing Gag and Nef proteins.
Herein we showed that NL4-3/DRT viral particle result an
efficient inductor of the cellular immune response against HIV-1
when used as a reagent in vitro in PBMC cultures. Additionally, we
also evaluated some clinical and immunological features of HIV
patients able to respond positively to this attenuated virus.
According to their safety profile and their relative low cost in
comparison to other compounds they could be considered as a
future candidate to be used as an effective immunogen in
therapeutic approaches or as an additional and useful reagent
for screening HIV-1-specific T cell responses in HIV infected
patients and to assess vaccine immunogenicity both in vitro and
in vivo.
Results
Retrotranscriptase Defective Virions Elicit Strong Specific
T cell Immune Response against HIV-1
We have developed a classical IFN-c-ELISPOT assay to
measure the immunogenic capacity in vitro of viral particles
produced from different NL4.3-based constructs. We have
compared both the proportion of positive responses elicited and
the intensity of the immune responses induced by a wild type NL4-
3 virus AT-2 inactivated (NL4-3+AT-2, o referred as wild type)
with RT-deleted genomes carrying both X4 (NL4-3/DRT) and
R5 envelope genes (NL4-3/DRT/DEnv[AC10]; NL4-3/DRT/
DEnv[Bal]) to assess the potential importance of co-receptor use
and RT deletion in triggering cellular responses.
By contrast, we did not include in our assay a non-attenuated
NL4-3 virus to avoid the potentially confounding effects of a
productive infectious virus able to replicate and integrate.
As it is shown in figure 1A the proportion of patients with
positive immune responses against NL4-3/DRT (DRT) virions
(55%) was significantly higher than to wild type (25%) (p,0.001)
[8] independently of the use of R5 or X4 receptors by viral
envelopes (51–53%). The magnitude of the response (SFC/106
cells) elicited by both the X4 and R5 DRT variants was also higher
than with wild type virus (p,0.001 and p,0.01, respectively), fact
that confirmed that this difference was also applicable to the
intensity of the response (fig. 1B).
We also assessed the T cell response to a DRT virus treated with
AT-2 to look at the potential effect of this pretreatment on
immune responses. As shown in Fig. 1A and B, no deleterious
effect was observed when we analyzed both the frequency and the
magnitude of positive cellular responses obtained when compared
to DRT virus non previously pretreated. Of note, we even
observed a better and higher response when our defective DRT
construct was additionally chemically inactivated.
Lastly, we also evaluated in parallel the response to Gag p24,
Gag p17, Gag small proteins (sp) and Nef peptide pools. As is
shown in Fig. 1A, percentages of HIV-infected individuals who
responded to theses peptide pools were significantly greater than to
the wild type whereas they were similar to the rate of response to
the different constructs of our defective virions (DRT). Moreover,
concerning the magnitude, response to Gag p24 and Nef peptide
pools was higher than to both wild type and DRT (Fig. 1B).
Figure 1. Comparison of frequencies and magnitudes of
responses against the different viral particles and peptides
pools tested. (A) Bars show the percentage of individuals with
positive response to the different constructs (Black bars) and the gag
p24, p17 and small proteins (sp) and nef peptide pools (White bars)
among the samples of HIV+ individuals tested. (B) Each symbol
represents the mean of SFC (spot forming cells/106 cells) 6 SEM
counted per condition after background subtraction. P values were
calculated using the Wilcoxon Matched-Pairs Ranks test for continuous
variables and x2-test for categorical variables. The magnitude of
response was significantly different among indicated stimuli (*p,0.05;
**p,0.01; ***p,0.001).
doi:10.1371/journal.pone.0058927.g001
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ICS Assay Confirmed ELISPOT Findings and Detected
Positive Responses in both Lineages: CD4 and CD8
HIV-1 specific immune responses were also measured by a 6
colour ICS assay in a subgroup of 21 HIV-infected patients
previously tested by ELISPOT (Fig. 2A). Total responses against
NL4-3/DRT were confirmed on 12 out of 16 (75%) of the
ELISPOT positive responders to these particles whereas only 4 out
of 13 (31%) wild type responders to ELISPOT were detected by
ICS. These results indirectly confirmed the higher and earlier
response obtained against DRT immature viral particles in
comparison with wild type AT-2 inactivated virus. In fact negative
response were described on 5 (100%) of the 5 negative ELISPOT
responders illustrating the specificity and reproducibility of the
detected response. On the other side, and as control, cytokine
production by HIV-p24-stimulated T cells was also measured in
parallel, and the results showed positive response in 15 out of 21
(71%) patients tested.
We next wanted to asses the different T cell lineage able to
respond to our DRT virus, and found that CD4+ T-cell responses
were present in 44% of the patients after stimulation with DRT
and in 50% of the individuals when stimulated in vitro with wild
type AT-2 inactivated. HIV-1- specific response rates for CD4+ T-
cells expressing IFN-c using the ICS assay were found to be
significantly higher after DRT stimulation (p = 0.017). By contrast,
percentages of specific T cells expressing other cytokines such as
IL-2 or TNF-a were similar against both stimuli (Fig. 2B). For
CD8+ T-cell responses, response rates observed were 31% and
25% after DRT and wild type AT-2 inactivated stimulation,
respectively. Lastly, positive responses detected simultaneously in
both CD4+ and CD8+ T cell subsets were only observed in two
individuals (12.5%). As previously mentioned, a pool of peptides
encompassing part of the p24 viral protein was used as a control of
HIV-specific T cell responses. As expected, this control induced
the highest values for all the cytokine-specific T cells evaluated in
both lineages (CD4 and CD8) when compared to virus particles
(Fig. 2B).
Differential Responses against Wild Type AT-2 Inactivated
and DRT Defined Three Different Patterns of HIV+
Individuals
Analysis of the immune response elicited against wild type AT-2
inactivated and DRT viruses showed a surprisingly result: each
patient responding to wild type virus also responded against DRT
virus, but not the other way around (i.e. 0% of patients responded
only against wild type AT-2 inactivated). This data allow us to
divide the study population into three different groups attending to
the profile of their in vitro response: full-responders, partial-
responders and non-responders.
Attending to the mentioned categorization of individuals, the
ELISPOT response obtained using overlapping HIV peptide pools
encompassing Gag and Nef proteins resulted in a different breadth
pattern (Fig. 3A). Full-responders individuals have a higher rate of
response against Gag peptides (p24, p17 and small proteins) (76–
86%) than partial-responders (52–67%) and non-responders (15–
41%), respectively whereas no difference were seen in terms of the
magnitude of the Gag specific T cell response (Fig. 3B). On the
other hand, Nef and HIV independent peptide pools (CEF
Citomegalovirus, Epstein-Barr and Influenza) elicited similar rate
of response in the three categories of patients with a significant
reduction in the total magnitude (SFC/106cells) of the response
mainly in the group of non-responders individuals (Fig. 3B).
We next assessed activation (CD38, HLA-DR and CD69) and
senescence markers (CD28) on T lymphocytes to characterize
more accurately immunological features of the three established
study groups of HIV-infected patients. Extracellular staining
revealed that baseline activation levels varied significantly between
full-responders and non-responders individuals in CD4+CD38+
and CD4+CD69+ T cell subsets (p,0.05) whereas were similar
when full and partial-responders were compared. Activation
markers on CD8+ T cells showed a similar tendency (Fig. 4).
Moreover, CD28 and HLA-DR surface markers were similarly
expressed in all the individuals tested in both CD4+ and CD8+ T
cell subsets (data not shown).
HLA Protective Alleles, Gender and Viral Load Levels
Correlated with the Elicited Response
Next we search for demographic and clinical parameters that
could be involved in the different pattern of T cell response
observed against viral particles. As shown in Table 1 and after
dividing HIV patients in the three different groups depending on
the T cell response profile found, we observed that full-responder
subjects comprised a significant higher percentage of women
(41.2%) than partial-responders (20%) and non-responders (3.7%).
Related with this bias and the way in which HIV transmission
takes place in women in this cohort (preferentially drug users) [9]
risk groups were also slightly different but without statistical
significance. Age was not related in any case with the response
elicited by the previously defined study groups.
Additionally, different clinical parameters such as plasma viral
load, NADIR CD4+, current CD4+ and CD8+ T cell counts,
VHC prevalence and HAART (high active antiretroviral treat-
ment) duration were considered (Table 2). We found that plasma
viral load was significantly lower in full-responder individuals,
surprisingly VHC prevalence did not affected the in vitro T cell
response. On the other hand, CD4 and CD8 T cell counts,
NADIR CD4 T cells, and median time of HAART were similar in
all the three groups pre-established of patients.
Finally another host factor associated with durable control of
HIV or better response to vaccines [10,11] is the presence of
certain HLA class I alleles, particularly HLA-B27and B57 [12–
16]. Other HLA-B alleles have also been associated with delayed
disease progression or lower viral loads, including HLA-B15, B51,
and B58 [17,18]. We then evaluated HLA class I frequencies in 38
patients from our study where HLA typing was available. In our
cohort among full-responders, 40% of the subjects expressed either
HLA-B27 or B57, while only 23% of non-responders carried these
alleles. As expected in a chronic asymptomatic cohort with a good
prognosis other protective alleles such as HLA-B15, B51, or B58,
were common in both groups (24% in full-responders vs 28% in
non-responders; Table 3) In any case the statistical analysis
performed using the Chi-square test to determine if this difference
between both populations was noteworthy, revealed that it was not
significant (p.0.05).
Additionally we found no association between protective HLA-
B status and IFN-c production to any HIV peptide pool or viral
particle tested in either full-responders or non-responders individ-
uals (data not shown). Thus, our data showed that there was no
apparent relationship between protective HLA-B alleles and the
capacity of HIV-specific CD4+ or CD8+ T-cells to express IFN-c
after stimulation with the viruses tested.
Lastly, and as our division of HIV patients according to the T
cell response profile observed also seems to be quite similar to the
standardized definition of the various clinical progression profiles:
elite controllers (EC), viremic controllers (VC) and chronic
progressors with or w/o treatment (CP), we looked at the
composition or proportion of EC, VC and CP in our three
groups of study. In this comparison EC raised up to 29.4% in full-
RT-Defective HIV Virions as an Immune Tool
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Figure 2. Example of IFN-c response in CD4 and CD8 T cell subsets from different individuals: full responder (FR) vs non-responder
(NR). (A) Representative dot plots of gating strategy used and cytokine responses detected using different stimuli. Box indicated the percentage of
IFN-c+ T cells. PMA-Ionophore was used as a positive control. (B) Evaluation of cytokine production in both subsets (CD4 and CD8). Percentage of T
cells producing IFN-c, TNF-a or IL-2 in response to virions (DRT or WT+AT2) or to a pool of peptides encompassing p24 is depicted.
doi:10.1371/journal.pone.0058927.g002
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Figure 3. Frequency of IFN-c-ELISPOT positive responses against different pools of peptides. (A) Population analyzed has been divided
attending to their positive response against WT+AT2 and/or DRT immunogens into three different groups (FR: full-responders; PR: partial-responders
and NR: non-responders). The response obtained against overlapping pools of peptides from Gag and Nef showed a different pattern between
established groups. Gag response was predominant in responder individuals (see results). CEF peptide pool was used as an HIV-independent peptide
stimulus. (B) Magnitude (SFC/106 PBMC) of HIV-1-specific T-cell responses against Gag (p24, p17 and p6-p7) protein was not affected among groups
whereas Nef present a significant reduction in non-responder individuals. Epitopes from human cytomegalovirus, Epstein-Barr virus and influenza
virus (CEF peptide pool) showed a higher magnitude in responder individuals. Statistically significant differences are shown (*p,0.05; **p,0.01;
***p,0.001).
doi:10.1371/journal.pone.0058927.g003
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responders individuals, whereas in partial-responders and non-
responders this percentage decreased to 13% and 0%, respectively.
On the other hand CP were more over-represented in the group of
non-responders (63%) than in those who respond at least to one
construction (29–35%) (Figure S1).
Discussion
The development of a vaccine to control the HIV/AIDS
pandemic has become an urgent priority and an international
goal. Big efforts have been done toward the development of
vaccines that induce effective T cell responses apart from produce
antibodies that can broadly neutralize HIV-1 [19]. In this context
validated assays and reagents to detect vaccine-induced HIV-
specific T cell responses has emerged as a powerful tool to identify
either potential future immunogens and epitope specificities of
multiple cytokine-secreting CD4+ and CD8+ T cells from
cryopreserved PBMC [20]. Although, there is no agreement on
the best methods or reagents for assaying the breadth and
magnitude of HIV-specific T cell responses. Many studies have
used IFN-c-ELISPOT assays and/or Intracellular Cytokyne
Staining (ICS) together with overlapping peptide sets to screen T
Figure 4. Percentage of expression of activation markers (CD38 and CD69) in CD4 and CD8 T cell subsets. Extracellular staining
revealed that baseline activation levels varied significantly between full-responders and non-responders HIV-infected individuals in CD4+CD38+ and
CD4+CD69+ subsets. Mann–Whitney P value is shown.
doi:10.1371/journal.pone.0058927.g004
Table 1. Demographic characteristics of the studied groups.
Full-responder (n = 17) Partial-responder (n = 25) Non-responder (n = 27)
Sex (p = 0,008**)
Male 10 (58.8%) 20 (80%) 26 (96.3%)
Female 7 (41.2%) 5 (20%) 1 (3.7%)
Age in years
Median 43.5 37 39
Range 29–64 22–61 27–64
Risk group
Homosexual 8 (47%) 17 (68%) 20 (74%)
Drug users 4 (23.5%) 2 (8%) 4 (14.8%)
Heterosexual 4 (23.5%) 6 (24%) 3 (11.2%)
Hemophilia 1 (5.9%) 0 0
doi:10.1371/journal.pone.0058927.t001
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cell responses [21,22]. Many factors need to be considered before
starting this approach as peptide length, purity, overlap, or pool
size. All these aspects remains actually controversial because of the
obtained differences in the elicited response [23,24]. It is well
known that 20-mer overlapping peptides detect CD4 T cell
responses in preference to CD8 T cell responses, whereas shorter
peptides of 15-mer seem to be more efficient for stimulating both
lineages (CD4 and CD8) [22]. If epitopes have been previously
mapped, optimal HLA class I-restricted, 9-mer peptides can be
used to increase sensitivity and specificity of the CD8 T cell
responses [6]. In any case and independently of the selected
approach, ELISPOT and/or ICS assays require large numbers of
PBMCs and expensive libraries of peptides. These libraries need to
pass previously a quality control to ensure they do not induce
unspecific results [7]. In addition, these peptide-based approaches
have other drawbacks, the extent to which the sequence of a
reference strain as well as the length and degree of peptide overlap
influence the detection of T cell responses is not well characterized
[23,25].
In our study we have evaluated a defective recombinant vector
(892 bp of the RT gene are deleted; pNL4-3/DRT) based on the
HIV-1 genome to be used as a reagent for detecting HIV specific
T cell responses and as future candidate to serve as immunogen in
therapeutic vaccine trials. Since HIV is a highly variable retrovirus
and differences in sequence between two viruses within a subtype
can be as high as 30%, constructing consensus sequences has been
proposed as an alternative to cover the required diversity of
subtypes [26,27]. Moreover these vectors have great potential
because they could carry optimized sequences of different HIV-1
genes that could improve the obtained response.
Antigen processing and presentation by DC is required for
optimal induction of HIV-1-specific T cell responses, which are
essential in controlling infection in vivo. This process is a complex
mechanism that involves many elements of the antigen processing
machinery localized in the endosomal compartment and/or the
cytosol [28]. Several works have showed that, for DC, little
amounts of antigens are sufficient for presentation on MHC
molecules and activation of T cells. Some of these approaches
have been done using antigens from non-replicating viruses,
including aldrithiol-2 (AT-2)-inactivated HIV-1 [29,30]. During
HIV-1 infection, most of circulating virus is not infectious [31].
Taking advantage of this phenomenon, defective and non-
replicating virions may constitute an interesting source of HIV-1
antigens for activation of HIV-1-specific CD4+ and CD8+ T cell
responses. In fact, our defective virus is an infectious but non-
replicating virus which conserves conformational and functionally
intact surface envelope proteins that can interact with T cells as
well as with surface receptors present on circulating dendritic cells
and monocytes. Therefore, we hypothesized that PBMCs may also
be useful to present antigens from fusion competent nonreplicating
virus (i.e. wild type AT-2 inactived and DRT) [30,32] and then to
detect HIV-specific T cell responses. The designed assay resulted
faster and cheaper although in comparison with DC the
percentage of positive responses was relatively lower [33].
Nevertheless our defective construct showed a better response (in
terms of frequency and magnitude; see fig. 1) in comparison with
AT-2 inactivated wild type virions. The potential mechanisms
responsible of such differences have been discussed elsewhere [8]
but it seems that probably, the maturation status of our defective
particle could imply a major stability which allows increased
peptide presentation and processing by APC. This result is really
interesting because the magnitude of a vaccine-induced responses
may be related to the potency and frequency of immunization,
which may also influence durability of the response [34]. As
Pantaleo et al. [35] describe the broader the antigen pool the
wider the T cell repertoire that can be mobilized. All this data
confirm that DRT can serve as an efficient source of antigen for
priming both CD4+ and CD8+ T cells (fig. 2A) and therefore
potentially function as a relevant source of antigen for priming
in vivo [28]. Another important advantage derives from the fact
that AT-2 treatment required previous studies of non-toxicity in
animal-models and GMP (Good manufacturing practice) condi-
tions that make it not suitable for be used in humans in our
country (personal communication from the AEMPS, Agencia
Española del Medicamento y Productos Sanitarios). DRT could be
included in clinical trials without attending all these requirements.







Plasma HIV RNA, median (IQR), copies/ml
50 (47–977) 1393 (50–4183) 508 (50–9222)
CD4+ T-cell count, mean (95% CI), cells/mm3
767 (587–947) 756 (630–883) 726 (595–857)
NADIR CD4+, mean (95% CI), cells/mm3
447 (377–517) 482 (390–573) 453 (381–526)
CD8+ T-cell count, mean (95% CI), cells/mm3
1041 (663–1418) 1173 (935–1411) 1223 (1069–1377)
Duration of HAART treatment prior to PBMC sample*, median (IQR), months
61 (45–120) 56 (30–105) 48 (24–76)
Prevalence of infection by VHC (%)
31 9 19
doi:10.1371/journal.pone.0058927.t002
Table 3. HLA-B subtypes carrier and allele frequencies in the asymptomatic population analyzed.
Responder population (n = 17) Non-responder population (n = 21)
n Carrier frequency Allele frequency n Carrier frequency Allele frequency
B27 4 23% 11% 2 9% 4.5%
B5701 3 17% 8.5% 3 14% 7%
B15 2 12% 6% 4 18% 9%
B51 1 6% 3% 1 5% 2.5%
B58 1 6% 3% 1 5% 2.5%
doi:10.1371/journal.pone.0058927.t003
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Moreover, and as we have shown, DRT could be considered as an
extremely useful reagent to detect the presence in vitro of HIV
specific T cell responses. Some of the advantages that we observed
using these virions were related with the feasibility, simplicity and
effective cost of the production of both the defective virus and the
assay. In fact, the use of our defective viruses would considerably
reduce the amount of cells required to perform an initial screening
of T cell responses. Moreover, and although stimulation with
defective virions resulted in lower levels of IFN-gamma T cell
responses in HIV-1-infected individuals, the response rate was
similar to the obtained after stimulating with HIV peptides.
Diverged response obtained between techniques (ICS and
ELISPOT), although previously described [36], could be ex-
plained by many reasons like different time of incubation between
techniques (see Methods, 6 hours instead of 16 hours), different
frequencies of specific-T cells response or different technical
sensitivity threshold. Concerning the different time of stimulation,
and although we can not be certain than longer incubation periods
could increase the response to the virions tested, it has been
described that measurement of IFN-g production is often optimal
after 6 h of simulation and not significantly improved with
increased incubation times [37]. So, we considered that a standard
6h-ICS could be sufficient to allow the detection of HIV-specific T
cells. On the other hand, it is well known that frequencies of T
cells recognizing individual antigens are very low. As a result of the
clonal expansion associated with infections, the frequency of
antigen-specific effector cells can rise up to 1:100, but these
frequencies normally settle in the range of 1:10,000 for effector
memory or memory [38], [39]. It is well established that ICS
measures intracellular cytokine whereas ELISPOT detects the
actually released product. Only the last one is biologically
functional, because cytokine production can be post-translationally
modified, meaning cytokine that is synthesized by a cell but not
released, will not exert any effector function in vivo. This premise
confirmed that our screening mainly conducted by the ELISPOT
assay is a good indicator of immune T cell response. Nevertheless,
we should consider that using a PBMC ELISPOT results include
all IFN-g-producing cells within the PBMC sample and not only
CD3+ T cells as by ICS.
Differential response against NL4-3+AT-2 and NL4-3/DRT
allowed us to define three different groups of HIV-infected
patients (full-responders, partial-responders and non-responders)
in a cohort of chronic asymptomatic HIV positive individuals.
This quite homogeneous population was divided in these three
categories attending to the elicited response and moreover, this
division seems to adequately correlate with different aspects of the
immunological state and disease progression. For instance the
higher rate of response against Gag peptides (76–86%; Fig. 3A)
observed in full-responders as well as the highest capacity to
respond to HIV independent peptides (CEF: CMV, Epstein-Barr
and Influenza) (Fig. 3B), and lastly the presence of lower levels of T
cell activation, which constituted a key aspect of HIV pathogenesis
[40], and lower levels of HIV viral replication, suggest that HIV-
infected individuals able to respond to our defective viral particle
should have a preserved functional immune system and conse-
quently a better prognosis and a more delayed clinical progression.
In fact, there was a greater percentage of HIV elite controllers
among the full-responders to our viral particles, additionally, and
as it has been described, a combination of host genetic and viral
factors supports current clinical definitions that discriminate
among patterns of HIV-1 progression [41]. In our case, 40% of
the full-responder individuals expressed HLA-B27 or B57, HLA
class I alleles associated with durable control of HIV [15,16,42]
and better response to vaccines [10,11], whereas only 23% of non-
responders subjects carried these alleles. Interestingly, we found a
significant higher rate of women in responder population (41,2%),
which were HLA-B27 carriers in a high frequency (43%). This
result could be responsible of the differential response elicited that
could be attributable to the presence or absence of this protective
allele [34]. So, the correlations observed between the elicited
response and the immunological state of the patients could be
useful to validate in one-step assay the eligibility of future
candidates to be included in therapeutic or prophylactic vaccine
trials.
In summary this kind of procedures and reagents allowed in vitro
immunogenicity comparisons between potential future immuno-
gens or vaccine candidates. IFN-c ELISPOT and intracellular
cytokine staining assays have been applied in the evaluation of T
cell responses against defective and/or inactivated non-replicative
viral particles (DRT or wild type AT-2 inactivated respectively).
Although we have to be cautious because a similar approach
during the evaluation of the Step trial detected high response rates
(90% in vaccinees after three immunizations) and the persistence
of the CD8+ T cell responses after 1 year, but it did not predict
vaccine efficacy [43]. The possibility to increase the immunoge-
nicity in a safer and more efficient way with these retro-
transcriptase defective virions that could carry optimized sequenc-
es of different HIV-1 genes and offer the possibility of construct
chimeric viral particles including sequences of autologous HIV
virus, postulated them as a useful tool. They could be used as an
effective immunogen or as an additional or alternative reagent for
screening HIV-1-specific T cell responses in both HIV seroposi-
tives and vaccinees. These viral particles were useful to screen in a
very simple manner our cohort and demonstrated a good
correlation with clinical and immunological features. Finally, the
implications of using reagents needing to be internalized and
processed by a cell, versus peptides for which no processing is
required, and peptides concentrations that are usually used in
excess, also need to be considered.
Materials and Methods
Generation of Virus Stocks
The X4 HIV strains used were the NL4-3 and the NL4-3/DRT
[8]. R5 HIV strains were the NL4-3/DRT/Denv[BaL] and NL4-
3/DRT/Denv[AC10], obtained by modifications of the NL4-3/
DRT (patent code EP 11382103.7).
Virus stocks were produced by transfecting 293-T cells with
different vectors derivated from the clone HIV-1 NL4-3 using the
calcium-phosphate method method (ProFectionH Mammalian
Transfection System; Promega, Madison, WI) according to the
manufacturer’s instructions. 5 mg of each purified DNA constructs
(Qiagen, Valencia, CA) were used for the transfection. The
supernatants were harvested two days and clarified by centrifu-
gation at 500 g/4uC for 10 min. Virus stocks were inactivated
with AT-2 treatment when required. To this aim a 100 mM stock
solution in DMSO (SIGMA-ALDRICH) was prepared and added
directly to virus to produce a 1 mM AT-2 solution and treated at
4uC over night [44,45]. Viral supernatants were concentrated
through ultracentrifugation (Sorvall Ultra Series WX Ultra 80;
Thermo Fisher Scientific, Asheville, NC). Viruses were quantified
by determining the concentration of p24 in the supernatant by an
antigen (Ag) capture assay (ELISA; Innogenetics NV, Gent,
Belgium).
Clinical Specimens
All the experiments made for measuring ELISPOT response
and Intracellular Cytokine staining (ICS) have been done using
RT-Defective HIV Virions as an Immune Tool
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58927
cryopreserved PBMC from up to 69 asymptomatic HIV positive
individuals in a cross-sectional study from treated and untreated
chronic asymptomatic HIV-1 individuals with baseline CD4+ T
lymphocyte counts .500 cells/mm3 and plasma viral loads
ranging from 50–10,000 HIV-1 RNA copies/mL (Hospital Clinic,
Barcelona, Spain). PBMCs were isolated by centrifugation through
a ficoll-hypaque gradient and cryopreserved. All cell cultures were
performed at 37uC in a fully humidified atmosphere with 5 %
CO2 in air. All the individuals gave informed written consent and
this study was reviewed and approved by the Institutional Ethical
Committee board of Hospital Clinic (Barcelona, Spain).
Enzyme-linked Immunospot (ELISPOT) Assay for IFN-c
Release
Ex vivo measurement of T cells for IFN-c production was
undertaken by the ELISPOT assay as previously described
[46,47]. Briefly, ninety-six-well plates (Multiscreen Millipore,
Bedford, MA) were coated overnight at 4uC with 15 mg/ml of
anti-IFN-c mAb 1-D1K (Mabtech, Stockholm, Sweden) in coating
buffer (Na2 CO3 0.1 M, pH 9.6). The plates were washed four
times and blocked with RPMI 1640/10% FBS. PBMCs were
added to the coated plates during 16–18 h at a final concentration
of 16105/100 ml. We have used peptide pools obtained from NIH
AIDS Reagent Program, spanning the entire HIV-1 consensus B
Gag and Nef proteins sequences. They consisted of 15-mer
peptides overlapping by 11, grouped in pools of 10–12 each (5 of
gag p24, 3 of gag p17, 2 of gag small proteins, and 2 of nef). All the
pools were used at a final concentration of 2 mg/ml. As described
above different constructions have been also used to evaluated this
issue (pNL4-3+AT-2; pNL4-3/DRT; pNL4-3/DRT+AT-2;
pNL4-3/DRT/DEnv[AC10] and pNL4-3/DRT/DEnv[Bal]). In
all cases we evaluated a dose of 200 ng/ml of HIV-1 p24.
Additionally a negative control (RPMI/10%FCS) and two positive
controls such as a pool of MHC class I-restricted T cell epitopes
from human cytomegalovirus, Epstein-Barr virus and influenza
virus (CEF, Mabtech) and phytohemagglutinin (PHA 2 mg/ml;
Sigma) were performed. The cells were lysed with PBS/0.05%
Tween 20, and the wells were incubated for 3 h with 1 mg/ml of
biotin-labelled, anti-IFN-c mAb 7-B6-1 (Mabtech). To visualize
the spot forming foci (IFN-c-secreting cells), the wells were washed
six times and treated during 1 h with streptavidin-alkaline
phosphatase (Mabtech). After this incubation the wells were
washed again and 100 ml/well of chromogenic alkaline phospha-
tase conjugated substrate (BioRad, Hercules, CA, USA) were
added. The spots were clearly visible in less than 30 minutes
avoiding direct light exposure. Spot forming cells (SFC) were
counted using an AID ELISPOT reader (Autoimmun Diagnostica
GmHb, Germany). Results were considered positive if the number
of SFC/106 PBMC in stimulated wells was twofold higher than
that in unstimulated control wells, and if there were at least
50 SFC/106 PBMC after background subtraction.
Activation Markers and Surface Staining
Subpopulations of CD3+, CD4+, and CD8+ cells were
determined by four-color flow cytometry. The following mono-
clonal antibodies were used: CD3-peridinin chlorophyll protein
(PerCP), CD4- allophycocyanin (APC), CD8-APC, CD28-fluor-
oisothiocyanate (FITC), HLA DR-FITC, CD57-FITC, CD69-
phycoerithrin (PE) and CD38-PE (all from Becton Dickinson,
Mountain View, CA). Mouse immunoglobulin isotypes conjugated
with Per-CP, PE, FITC or APC were always used as negative
controls for nonspecific binding. The stained cells were analyzed
on a FACSCalibur (Becton Dickinson, San Jose, CA) flow
cytometer. Lymphocytes were gated on the basis of forward and
side scatter parameters. The gating region was referred to an FL3/
SS histogram, where an FL3+ (CD3+) region was defined. This
region was further analyzed for the expression of FL1, FL2 and
FL4. Data were analyzed using FlowJo Software (Tree Star).
ICS Assay
Intracellular staining profile were analyzed by ICS as described
previously elsewhere [48]. Briefly, cryopreserved PBMC were
thawed, washed and resuspended in RPMI1640 with v/v 10%
FCS and then incubated overnight. Cells were seeded on M96
plates and stimulated with NL4-3 and NL4-3/DRT virions at a
final concentration of 200 ng/ml. A p24 peptide-pool and PMA-
Ionophore stimulus were also used as positive controls (2 mgr/ml
and 50 ng/ml-500 ng/ml at a final concentration, respectively).
Protein transport inhibitors Monensin (GolgiStop, BD Pharmin-
gen) were added after set-up for the different stimuli and cells were
incubated at 37uC, 5% CO2 during 6 hours. After stimulation,
cells were washed, stained for the surface markers, fixed,
permeabilized using the BD Cytofix/CytopermTM Kit (Becton
Dickinson) and stained intracellularly using the appropriate
fluorochromes. Cells were acquired using a FACsCanto flow
cytometer (Becton Dickinson) and the number of events ranged
between 26105 and 106.
Intracellular staining have been analyzed as follows: lympho-
cytes were gated on a forward scatter area versus side scatter area
pseudo-color dot plot, then on CD3+ (APC-Cy7), and from there,
CD4+ (PE-Cy7) and CD8+ (PerCP Cy5.5) subsets are identified.
Each of those two subsets producing IFN-c, TNF-a and IL-2 were
subsequently identified in the corresponding channel (APC, PE
and FITC respectively). Percentages of stimulated cytokine-
producing T cells were considered positive when values were
three times higher than the non-stimulated background.
HLA Typing
HLA class I typing was carried out at Servicio de Inmunologı́a,
CDB (Hospital Clinic i Provincial de Barcelona, Spain). Briefly,
HLA loci were molecularly typed with DNA extracted from
PBMCs using QIAmp Blood Kit (Qiagen, Valencia, CA). The
HLA class I genotype was determined by reverse sequence-specific
oligonucleotide (SSO) (RELITM Dynal, Madrid, Spain). Allele
definition was automatically assigned by the RELITM SSO
Pattern matching program software and was manually supervised
[46].
Statistical Analysis
Median and interquartile range (IQR) were used to describe
each of the continuous variables analyzed. Data analysis and
comparisons for the different parameters were made using
parametric (t-student) and nonparametric (e.g. Mann-Whitney or
Wilcoxon) tests as appropriate. For comparisons of multiple groups
the Kruskal-Wallis test was performed with correction using
Dunn’s multiple comparison test. Statistical analysis was per-
formed using SPSS 18.0 (Windows) software (SPSS Inc, Chicago,
IL) and GraphPad Software, San Diego California USA
(GraphPad Prism version 5.00). For all analyses, the level of
significance was set at p,0.05.
Supporting Information
Figure S1 Distribution of the different clinical progres-
sion profiles (EC, VC and CP+HAART) within the groups
described previously (FR: full-responders; PR: partial-
responders and NR: non-responders).
(TIF)
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